AI Prospecting for Biogen
Company data:
Company size:
7570 employeesWebsite URL:
https://www.biogen.comIndustry
BiotechnologyHeadquarters:
Cambridge, Massachusetts, USAInvestment round:
Publicly Traded (NASDAQ: BIIB)ARR:
$10 billionLatest news about Biogen
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Biogen's latest significant news includes the approval of “LEQEMBI®” (Lecanemab) for the treatment of early Alzheimer's disease in Mexico, as well as its launch in South Korea. Additionally, Biogen and Samsung Bioepis received European Commission approval for the aflibercept biosimilar, OPUVIZ™[2][3].
Biogen announced that Eisai completed the rolling submission to the US FDA for the Biologics License Application for subcutaneous maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease under Fast Track status[3].
Biogen appointed Daniel Quirk, MD, as the new Chief Medical Officer and reported its third quarter 2024 results. The company also announced a multi-target research collaboration with Neomorph to discover and develop molecular glue degraders for Alzheimer’s, rare, and immunological diseases[3].
Open job positions at Biogen
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Scientist I/II, Gene Therapy - DMPK
Associate Scientist III – Fluid Biomarker Assay Development
Scientist I/II – Gene Therapy – Vector Production and Purification
